يعرض 361 - 380 نتائج من 7,166 نتيجة بحث عن 'significantly ((((((largest decrease) OR (we decrease))) OR (greater decrease))) OR (nn decrease))', وقت الاستعلام: 0.33s تنقيح النتائج
  1. 361

    Kato Katz and PCR database 12 months collection. حسب Jannet A. Tobon Ramos (20855642)

    منشور في 2025
    "…Twelve months post-MDA, hookworm prevalence decreased to 56.5% in DA- and 34.4% in IDA-treated villages, respectively (<i>p</i><0.001, both comparisons). …"
  2. 362

    Master database baseline, 4 weeks and 1 year. حسب Jannet A. Tobon Ramos (20855642)

    منشور في 2025
    "…Twelve months post-MDA, hookworm prevalence decreased to 56.5% in DA- and 34.4% in IDA-treated villages, respectively (<i>p</i><0.001, both comparisons). …"
  3. 363
  4. 364
  5. 365

    Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> حسب Chang Seok Han (21814121)

    منشور في 2025
    "…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …"
  6. 366
  7. 367
  8. 368

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
  9. 369

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
  10. 370

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
  11. 371
  12. 372
  13. 373
  14. 374
  15. 375
  16. 376
  17. 377
  18. 378
  19. 379
  20. 380